{
  "docId": "019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "docSlug": "213575480fcc7466657230c6a0d87626",
  "documentTitle": "23andMe | Investor Day Presentation Deck | 78 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 48,
  "pageCount": 78,
  "prevPage": 47,
  "nextPage": 49,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f0b8-737f-9ff6-e8b6f7a1e960/48",
  "deckHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "deckJsonHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960.json",
  "deckAnchorHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960#slide-48",
  "components": [
    {
      "bbox": {
        "h": 0.167,
        "w": 0.911,
        "x": 0.044,
        "y": 0.411
      },
      "kind": "list",
      "text": "Combining components of the CD226 pathway may be more efficacious than inhibiting single components, but will require complex clinical trials. GSK has the relevant agents to target the CD226 axis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a3b5723-c15f-4e5c-b14e-812aa54987aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.167,
        "w": 0.911,
        "x": 0.044,
        "y": 0.622
      },
      "kind": "list",
      "text": "The Phase 1 clinical trial with GSK'608 (anti-CD96) and dostarlimab is ongoing (conducted by GSK). Data is expected in 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cd6bca6-e8a7-43e9-ba89-4410772d5ab1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.111,
        "w": 0.911,
        "x": 0.044,
        "y": 0.256
      },
      "kind": "list",
      "text": "The 23andMe immuno-oncology signature has highlighted the importance of the CD226 pathway which includes CD96 and TIGIT",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f35450e-0a6a-4688-a1b7-0c5aec611ef3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.178,
        "w": 0.911,
        "x": 0.044,
        "y": 0.056
      },
      "kind": "title",
      "text": "CD96 is Part of the Genetically-validated CD226 Axis and is Progressing in Clinical Development",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb18d819-8503-4515-b3bd-8fcfd1d54db3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}